The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$812,546 ปริมาณ
Sep 30, 2026
September 30
2%
December 31
22%
$812,546 ปริมาณ
September 30
$739 ปริมาณ
2%
December 31
$202,236 ปริมาณ
22%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Jul 31, 2026, 5:46 PM ET
ปริมาณการซื้อขาย
$812,546วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Jul 31, 2026, 5:46 PM ETผู้ตัดสินผล
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$812,546วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Jul 31, 2026, 5:46 PM ETผู้ตัดสินผล
0x65070BE91...The Trump administration advanced marijuana rescheduling through an April 2026 final order moving FDA-approved products and state-licensed medical cannabis to Schedule III, while a separate administrative hearing on broader rescheduling from Schedule I opened June 29 and closed its record by July 15. Testimony included an opposition expert conceding that marijuana meets Schedule III criteria under the Controlled Substances Act. The DEA administrative law judge’s recommendation remains pending, after which the DEA administrator will issue a final rule subject to expected litigation. A federal appeals court recently rejected challenges seeking to halt the process, and states such as Alabama have withdrawn procedural objections. These steps, following a December 2025 executive order directing expedited review, shape trader assessments of timelines for full rescheduling.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย